Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of HER2-Specific CAR T Cell Locoregional Immunotherapy for HER2 Positive Recurrent/Refractory Pediatric Central Nervous System Tumors

NCT03500991 is registered in ClinicalTrials.gov with Seattle Children's Hospital as lead sponsor.

NCT NCT03500991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03500991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of HER2-Specific CAR T Cell Locoregional Immunotherapy for HER2 Positive Recurrent/Refractory Pediatric Central Nervous System Tumors
Lead sponsor
Seattle Children's Hospital
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 26, 2018
Completion date
July 26, 2039
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atypical teratoid/rhabdoid tumor, central nervous system tumor, pediatric, choroid plexus carcinoma, ependymoma, germ cell tumor, glioma, medulloblastoma, pineoblastoma, primitive neuroectodermal tumor